Clinical significance of gastrin receptors in human colon cancers

J. R. Upp, Pomila Singh, Courtney Townsend, J. C. Thompson

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

We have measured gastrin receptors (GR) in surgical specimens from 67 patients with primary colon cancers in order to determine the clinical significance of GR in colon cancer. GR analysis was performed on these specimens, and 22 cancers (32.8%) had no detectable GR. Thirty-eight cancers (56.7%) had high-affinity (K(d) < 1.0 nM) levels of GR. Seven cancers (10.4%) had only low-affinity GR (K(d) > 1.0 nM). Twenty patients (29.9%) had cancers with GR > 10 fmol/mg protein. Mean GR content was significantly greater (11.8 ± 2.9 fmol/mg protein) in Dukes' Stage A and B cancers when compared to Stage C and D cancers (6.2 ± 1.6 fmol/mg protein). A significantly greater percentage (52.4%) of patients in the early stages (A and B) had tumors with > 10 fmol/mg protein compared to patients with more advanced (C and D) cancers (19.6%). GR content did not correlate with histological differentiation, patient age, or preoperative carcinoembryonic antigen levels. No difference in the GR content was noted between left and right colon cancers or in patients of different sex or race. GR content of normal colon mucosa correlated with the GR content of colon cancers from the same surgical specimen, suggesting that these tumors maintain their normal complement in GR. In the early period of follow-up, 12 of 43 (28%) Stage C and D patients with GR < 10 fmol/mg protein have died, whereas all 8 Stage C and D patients with GR > 10 fmol/mg protein are alive. GR content of colon cancers may have prognostic significance and may identify a group of patients with colon cancer that may benefit from hormonal therapy with antigastrin drugs.

Original languageEnglish (US)
Pages (from-to)488-492
Number of pages5
JournalCancer Research
Volume49
Issue number2
StatePublished - 1989

Fingerprint

Cholecystokinin B Receptor
Colonic Neoplasms
Neoplasms
Proteins
Carcinoembryonic Antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical significance of gastrin receptors in human colon cancers. / Upp, J. R.; Singh, Pomila; Townsend, Courtney; Thompson, J. C.

In: Cancer Research, Vol. 49, No. 2, 1989, p. 488-492.

Research output: Contribution to journalArticle

@article{68c3041f2c364f81a5fea2d32614223f,
title = "Clinical significance of gastrin receptors in human colon cancers",
abstract = "We have measured gastrin receptors (GR) in surgical specimens from 67 patients with primary colon cancers in order to determine the clinical significance of GR in colon cancer. GR analysis was performed on these specimens, and 22 cancers (32.8{\%}) had no detectable GR. Thirty-eight cancers (56.7{\%}) had high-affinity (K(d) < 1.0 nM) levels of GR. Seven cancers (10.4{\%}) had only low-affinity GR (K(d) > 1.0 nM). Twenty patients (29.9{\%}) had cancers with GR > 10 fmol/mg protein. Mean GR content was significantly greater (11.8 ± 2.9 fmol/mg protein) in Dukes' Stage A and B cancers when compared to Stage C and D cancers (6.2 ± 1.6 fmol/mg protein). A significantly greater percentage (52.4{\%}) of patients in the early stages (A and B) had tumors with > 10 fmol/mg protein compared to patients with more advanced (C and D) cancers (19.6{\%}). GR content did not correlate with histological differentiation, patient age, or preoperative carcinoembryonic antigen levels. No difference in the GR content was noted between left and right colon cancers or in patients of different sex or race. GR content of normal colon mucosa correlated with the GR content of colon cancers from the same surgical specimen, suggesting that these tumors maintain their normal complement in GR. In the early period of follow-up, 12 of 43 (28{\%}) Stage C and D patients with GR < 10 fmol/mg protein have died, whereas all 8 Stage C and D patients with GR > 10 fmol/mg protein are alive. GR content of colon cancers may have prognostic significance and may identify a group of patients with colon cancer that may benefit from hormonal therapy with antigastrin drugs.",
author = "Upp, {J. R.} and Pomila Singh and Courtney Townsend and Thompson, {J. C.}",
year = "1989",
language = "English (US)",
volume = "49",
pages = "488--492",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical significance of gastrin receptors in human colon cancers

AU - Upp, J. R.

AU - Singh, Pomila

AU - Townsend, Courtney

AU - Thompson, J. C.

PY - 1989

Y1 - 1989

N2 - We have measured gastrin receptors (GR) in surgical specimens from 67 patients with primary colon cancers in order to determine the clinical significance of GR in colon cancer. GR analysis was performed on these specimens, and 22 cancers (32.8%) had no detectable GR. Thirty-eight cancers (56.7%) had high-affinity (K(d) < 1.0 nM) levels of GR. Seven cancers (10.4%) had only low-affinity GR (K(d) > 1.0 nM). Twenty patients (29.9%) had cancers with GR > 10 fmol/mg protein. Mean GR content was significantly greater (11.8 ± 2.9 fmol/mg protein) in Dukes' Stage A and B cancers when compared to Stage C and D cancers (6.2 ± 1.6 fmol/mg protein). A significantly greater percentage (52.4%) of patients in the early stages (A and B) had tumors with > 10 fmol/mg protein compared to patients with more advanced (C and D) cancers (19.6%). GR content did not correlate with histological differentiation, patient age, or preoperative carcinoembryonic antigen levels. No difference in the GR content was noted between left and right colon cancers or in patients of different sex or race. GR content of normal colon mucosa correlated with the GR content of colon cancers from the same surgical specimen, suggesting that these tumors maintain their normal complement in GR. In the early period of follow-up, 12 of 43 (28%) Stage C and D patients with GR < 10 fmol/mg protein have died, whereas all 8 Stage C and D patients with GR > 10 fmol/mg protein are alive. GR content of colon cancers may have prognostic significance and may identify a group of patients with colon cancer that may benefit from hormonal therapy with antigastrin drugs.

AB - We have measured gastrin receptors (GR) in surgical specimens from 67 patients with primary colon cancers in order to determine the clinical significance of GR in colon cancer. GR analysis was performed on these specimens, and 22 cancers (32.8%) had no detectable GR. Thirty-eight cancers (56.7%) had high-affinity (K(d) < 1.0 nM) levels of GR. Seven cancers (10.4%) had only low-affinity GR (K(d) > 1.0 nM). Twenty patients (29.9%) had cancers with GR > 10 fmol/mg protein. Mean GR content was significantly greater (11.8 ± 2.9 fmol/mg protein) in Dukes' Stage A and B cancers when compared to Stage C and D cancers (6.2 ± 1.6 fmol/mg protein). A significantly greater percentage (52.4%) of patients in the early stages (A and B) had tumors with > 10 fmol/mg protein compared to patients with more advanced (C and D) cancers (19.6%). GR content did not correlate with histological differentiation, patient age, or preoperative carcinoembryonic antigen levels. No difference in the GR content was noted between left and right colon cancers or in patients of different sex or race. GR content of normal colon mucosa correlated with the GR content of colon cancers from the same surgical specimen, suggesting that these tumors maintain their normal complement in GR. In the early period of follow-up, 12 of 43 (28%) Stage C and D patients with GR < 10 fmol/mg protein have died, whereas all 8 Stage C and D patients with GR > 10 fmol/mg protein are alive. GR content of colon cancers may have prognostic significance and may identify a group of patients with colon cancer that may benefit from hormonal therapy with antigastrin drugs.

UR - http://www.scopus.com/inward/record.url?scp=0024581428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024581428&partnerID=8YFLogxK

M3 - Article

C2 - 2910467

AN - SCOPUS:0024581428

VL - 49

SP - 488

EP - 492

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 2

ER -